Prophylactic Medicaments Containing Insulin Market

The article provides detailed insights into the global market for medicaments containing insulin but not antibiotics in measured doses. It includes projections for consumption and value trends up to 2030, highlighting the market performance and anticipated growth rates. The analysis covers key metrics such as market volume, value, production, import, and export data, as well as the main countries involved in the market. Overall, the market is expected to continue an upward trend, with significant growth opportunities in the coming years.

Market Forecast

Driven by increasing demand for medicaments containing insulin but not antibiotics in measured doses worldwide, the market is expected to continue an upward consumption trend over the next eight years. Market performance is forecast to decelerate, expanding with an anticipated CAGR of +5.9% for the period from 2022 to 2030, which is projected to bring the market volume to 12M tons by the end of 2030.

In value terms, the market is forecast to increase with an anticipated CAGR of +8.4% for the period from 2022 to 2030, which is projected to bring the market value to $4,361.2B (in nominal prices) by the end of 2030.

Consumption

World Consumption of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

In 2022, global consumption of medicaments containing insulin but not antibiotics in measured doses stood at 7.5M tons, remaining constant against the year before. Overall, the total consumption indicated strong growth from 2012 to 2022: its volume increased at an average annual rate of +7.4% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2022 figures, consumption decreased by -0.3% against 2020 indices. Global consumption peaked at 7.5M tons in 2020; afterwards, it flattened through to 2022.

The global prophylactic medicaments containing insulin market value stood at $2,286.4B in 2022, picking up by 2.9% against the previous year. This figure reflects the total revenues of producers and importers (excluding logistics costs, retail marketing costs, and retailers' margins, which will be included in the final consumer price). Over the period under review, the total consumption indicated a prominent expansion from 2012 to 2022: its value increased at an average annual rate of +6.7% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2022 figures, consumption decreased by -2.8% against 2020 indices. Over the period under review, the global market attained the peak level at $2,351.5B in 2020; however, from 2021 to 2022, consumption remained at a lower figure.

Consumption By Country

The countries with the highest volumes of consumption in 2022 were China (1.8M tons), the United States (1.4M tons) and India (721K tons), with a combined 52% share of global consumption.

From 2012 to 2022, the biggest increases were recorded for the United States (with a CAGR of +11.5%), while consumption for the other global leaders experienced more modest paces of growth.

In value terms, the largest prophylactic medicaments containing insulin markets worldwide were China ($926.7B), Germany ($613.1B) and the United States ($181.6B), with a combined 75% share of the global market.

China, with a CAGR of +13.7%, recorded the highest growth rate of market size in terms of the main consuming countries over the period under review, while market for the other global leaders experienced more modest paces of growth.

The countries with the highest levels of prophylactic medicaments containing insulin per capita consumption in 2022 were Germany (5 kg per person), Canada (4.7 kg per person) and the UK (4.2 kg per person).

From 2012 to 2022, the biggest increases were recorded for the United States (with a CAGR of +10.8%), while consumption for the other global leaders experienced more modest paces of growth.

Production

World Production of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

In 2022, approx. 7.4M tons of medicaments containing insulin but not antibiotics in measured doses were produced worldwide; approximately mirroring 2021. Overall, the total production indicated a prominent expansion from 2012 to 2022: its volume increased at an average annual rate of +7.4% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2022 figures, production decreased by -0.2% against 2020 indices. The pace of growth was the most pronounced in 2013 when the production volume increased by 17% against the previous year. Global production peaked at 7.5M tons in 2020; however, from 2021 to 2022, production failed to regain momentum.

In value terms, prophylactic medicaments containing insulin production expanded slightly to $2,288.2B in 2022 estimated in export price. Over the period under review, the total production indicated a strong expansion from 2012 to 2022: its value increased at an average annual rate of +6.7% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2022 figures, production decreased by -3.5% against 2020 indices. The pace of growth was the most pronounced in 2013 with an increase of 30% against the previous year. Over the period under review, global production reached the peak level at $2,370.9B in 2020; however, from 2021 to 2022, production remained at a lower figure.

Production By Country

The countries with the highest volumes of production in 2022 were China (1.8M tons), the United States (1.4M tons) and India (722K tons), with a combined 52% share of global production.

From 2012 to 2022, the biggest increases were recorded for the United States (with a CAGR of +11.5%), while production for the other global leaders experienced more modest paces of growth.

Imports

World Imports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

In 2022, purchases abroad of medicaments containing insulin but not antibiotics in measured doses decreased by -10.2% to 37K tons, falling for the second year in a row after three years of growth. The total import volume increased at an average annual rate of +3.5% over the period from 2012 to 2022; however, the trend pattern indicated some noticeable fluctuations being recorded in certain years. The pace of growth was the most pronounced in 2013 when imports increased by 14%. Over the period under review, global imports hit record highs at 42K tons in 2020; however, from 2021 to 2022, imports failed to regain momentum.

In value terms, prophylactic medicaments containing insulin imports reduced notably to $8.3B in 2022. Over the period under review, imports continue to indicate a mild descent. The most prominent rate of growth was recorded in 2013 with an increase of 16%. Over the period under review, global imports attained the maximum at $12.6B in 2014; however, from 2015 to 2022, imports failed to regain momentum.

Imports By Country

The United States (4.7K tons) and France (3.4K tons) represented roughly 22% of total imports in 2022. It was followed by Germany (2.2K tons), Turkey (2.1K tons) and Canada (1.7K tons), together comprising a 16% share of total imports. Algeria (1,234 tons), Japan (1,108 tons), Spain (922 tons), Hungary (864 tons), Italy (830 tons), Iran (798 tons), Colombia (795 tons) and China (786 tons) followed a long way behind the leaders.

From 2012 to 2022, the most notable rate of growth in terms of purchases, amongst the key importing countries, was attained by Iran (with a CAGR of +32.5%), while imports for the other global leaders experienced more modest paces of growth.

In value terms, the United States ($1.2B), France ($1.1B) and Germany ($614M) constituted the countries with the highest levels of imports in 2022, with a combined 34% share of global imports. Canada, Japan, China, Algeria, Iran, Hungary, Turkey, Italy, Spain and Colombia lagged somewhat behind, together accounting for a further 26%.

Iran, with a CAGR of +30.3%, saw the highest growth rate of the value of imports, in terms of the main importing countries over the period under review, while purchases for the other global leaders experienced more modest paces of growth.

Import Prices By Country

In 2022, the average prophylactic medicaments containing insulin import price amounted to $222,415 per ton, falling by -11.5% against the previous year. In general, the import price recorded a perceptible contraction. The most prominent rate of growth was recorded in 2013 when the average import price increased by 1.8%. Global import price peaked at $373,438 per ton in 2014; however, from 2015 to 2022, import prices stood at a somewhat lower figure.

Prices varied noticeably by country of destination: amid the top importers, the country with the highest price was China ($391,216 per ton), while Colombia ($75,606 per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by France (+1.6%), while the other global leaders experienced a decline in the import price figures.

Exports

World Exports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

In 2022, shipments abroad of medicaments containing insulin but not antibiotics in measured doses increased by 13% to 28K tons, rising for the second consecutive year after two years of decline. The total export volume increased at an average annual rate of +3.9% over the period from 2012 to 2022; the trend pattern remained relatively stable, with somewhat noticeable fluctuations being recorded throughout the analyzed period. The pace of growth was the most pronounced in 2013 with an increase of 37% against the previous year. The global exports peaked in 2022 and are likely to see steady growth in years to come.

In value terms, prophylactic medicaments containing insulin exports declined to $7.1B in 2022. In general, exports recorded a relatively flat trend pattern. The pace of growth appeared the most rapid in 2013 when exports increased by 28%. The global exports peaked at $9.8B in 2014; however, from 2015 to 2022, the exports failed to regain momentum.

Exports By Country

In 2022, France (12K tons) represented the main exporter of medicaments containing insulin but not antibiotics in measured doses, achieving 41% of total exports. The United States (3.4K tons) held a 12% share (based on physical terms) of total exports, which put it in second place, followed by Italy (8.2%), India (7.1%), Germany (6.7%), China (5.3%) and Brazil (4.8%).

From 2012 to 2022, average annual rates of growth with regard to prophylactic medicaments containing insulin exports from France stood at +7.1%. At the same time, China (+44.4%), Italy (+9.6%) and the United States (+4.3%) displayed positive paces of growth. Moreover, China emerged as the fastest-growing exporter exported in the world, with a CAGR of +44.4% from 2012-2022. Germany experienced a relatively flat trend pattern. By contrast, India (-6.4%) and Brazil (-8.4%) illustrated a downward trend over the same period. From 2012 to 2022, the share of France, China and Italy increased by +11, +5.1 and +3.4 percentage points, respectively. The shares of the other countries remained relatively stable throughout the analyzed period.

In value terms, the largest prophylactic medicaments containing insulin supplying countries worldwide were Germany ($2.4B), France ($1.9B) and China ($799M), with a combined 71% share of global exports.

China, with a CAGR of +50.7%, saw the highest growth rate of the value of exports, in terms of the main exporting countries over the period under review, while shipments for the other global leaders experienced more modest paces of growth.

Export Prices By Country

The average prophylactic medicaments containing insulin export price stood at $252,804 per ton in 2022, dropping by -16.8% against the previous year. Over the period under review, the export price recorded a perceptible curtailment. The most prominent rate of growth was recorded in 2014 when the average export price increased by 8.5%. As a result, the export price attained the peak level of $365,795 per ton. From 2015 to 2022, the average export prices remained at a somewhat lower figure.

There were significant differences in the average prices amongst the major exporting countries. In 2022, amid the top suppliers, the country with the highest price was Germany ($1,245,541 per ton), while Brazil ($43,917 per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by India (+5.2%), while the other global leaders experienced more modest paces of growth.

Source: IndexBox Market Intelligence Platform